Vaxxas
Vaxxas is commercializing a novel vaccination technology that dramatically enhances the performance of existing and next-generation vaccines.
1
Funding Rounds
$22.8m
Money raised
Overview
Vaxxas is commercializing a novel vaccination technology that dramatically enhances the performance of existing and next-generation vaccines.
-
Website:
- Social accounts:
Funding series
Funding Series Analysis
The company Vaxxas has raised a total of $22.82m in funding over 1 rounds.
Key Insights:
- Vaxaas - Series C round, December 2022: $22.82m
Vaxaas - Series C round, December 2022
$22.82m
Industries
Vaxxas is active in the following industries: